8-K: Cosmos Health Reports Record 2025 Revenue of $65.3M

Cosmos Health achieved record annual revenue of $65.3 million in 2025, representing a 20% year-over-year increase.

Summary

• Annual revenue reached a record $65.3 million, a 20% increase from $54.4 million in 2024.
• Gross profit grew 83% to $7.9 million, with gross margins expanding 418 basis points to 12.1%.
• Adjusted EBITDA improved slightly to a loss of $3.36 million, compared to a loss of $3.44 million in 2024.
• Net loss for the year was $19.14 million, compared to a $16.18 million loss in 2024.
• Cash and cash equivalents increased significantly to $3.46 million from $0.32 million in the prior year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed result; while operational growth and revenue records are positive, the persistent net losses and reliance on complex non-cash adjustments and digital asset strategies introduce significant volatility.

Positives

• Record annual revenue of $65.3 million, up 20% year-over-year.
• Gross profit surged 83% to $7.9 million.
• Gross margin expansion of 418 basis points to 12.1%.
• Cash position improved tenfold to $3.5 million.
• Adjusted EPS improved by 82% to ($0.12) from ($0.65).
• Secured long-term contract manufacturing agreements for over 12 million units.

Negatives

• Reported a net loss of $19.14 million for the fiscal year.
• Total operating expenses increased to $24.60 million from $19.86 million.
• Significant provisions for doubtful accounts totaling $6.41 million.
• Total liabilities increased to $47.05 million from $29.78 million.
• Stockholders equity decreased to $18.42 million from $24.53 million.

Risks

• Ongoing net losses and negative cash flow from operations.
• Exposure to digital asset volatility through Ethereum treasury strategy.
• Reliance on external financing to fund growth and business plans.
• Geopolitical risks including the war in Ukraine and Middle East conflicts.
• High levels of accounts receivable and provisions for doubtful accounts.

Future Outlook

The company reports strong momentum continuing into 2026 across all core segments and plans to provide updated guidance in the near term. Strategic focus remains on U.S. expansion, R&D pipeline advancement, and digital asset treasury management.

Management Comments

• 2025 was the year Cosmos Health proved its model. Not with promises with numbers.
• These are not incremental improvements. This is the structural transformation of a healthcare platform.
• I personally increased my ownership by over 3.3 million shares in 2025... because I believe with full conviction that the intrinsic value of Cosmos Health is a significant multiple of where this stock trades today.

Industry Context

StockSavvy.ai notes that Cosmos Health is attempting to pivot from a traditional distribution model to a vertically integrated, high-margin manufacturing and R&D platform. The company's aggressive entry into the U.S. market and adoption of a digital asset treasury strategy are unconventional for a mid-cap healthcare firm, reflecting a high-risk, high-reward growth strategy.

Comparison to Industry Standards

• Revenue growth of 20% outperforms many legacy pharmaceutical distributors.
• Gross margins of 12.1% remain below top-tier global pharmaceutical manufacturers, which often exceed 40-50%.
• The company's reliance on non-GAAP adjustments to reach an 'Adjusted EBITDA' loss is common in early-stage growth companies but highlights ongoing profitability challenges compared to established peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution or volatility from financing facilities and digital asset strategy.
• Creditors: Increased debt load from new credit facilities and bond loans.
• Employees: Expansion of headcount in scientific and sales roles.

Next Steps

• Provide updated 2026 guidance in the near term.
• Continue U.S. expansion of NOOR Collagen.
• Advance R&D pipeline including CCX0722 weight management product.
• Evaluate strategic options to unlock value from real estate assets.

Key Dates

Recommendation

While the company is showing strong top-line growth and operational scaling, the persistent net losses and unconventional treasury strategies warrant a cautious 'hold' until the company demonstrates a clear path to GAAP profitability.

Keywords

Cosmos Health, COSM, Healthcare, Pharmaceuticals, Nutraceuticals, Contract Manufacturing, Financial Results, Digital Assets